Stable Isotope Labelled Concizumab Biosimilar – Anti-TFPI mAb – Research Grade

Reference: PX-TA1306-SIL-1MG
Size

Brand

Product type

Clonality

Expression system

Applications

Product nameStable Isotope Labelled Concizumab Biosimilar - Anti-TFPI mAb - Research Grade
SourceCAS 1312299-39-0
SpeciesHumanized
Expression systemMammalian cells
Purity>95%
BufferPBS buffer PH7.5
Delivery conditionBlue Ice
Delivery Time3-5 days if in stock; 5-8 weeks if production needed
Storage conditionstore at -80°C
BrandProteoGenix
ApplicationsMS
Aliases /SynonymsAnti-TFPI,NN7415,mab2021
ReferencePX-TA1306-SIL
NoteFor research use only. Not suitable for clinical or therapeutic use.
IsotypeIgG4-kappa
ClonalityMonoclonal Antibody
FormatLyophilized
LabellingArginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99%
Isotopic Enrichment99%
Stability1 year

Description of Concizumab Biosimilar - Anti-TFPI mAb - Research Grade

General information on Anti-TFPI[Homo sapiens] (Concizumab) Monoclonal Antibody

Concizumab has been investigated for the treatment of Haemophilia A and Congenital Bleeding Disorder.

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “Stable Isotope Labelled Concizumab Biosimilar – Anti-TFPI mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Contact us

Send us a message from the form below







    Cart (0 Items)

    Your cart is currently empty.

    View Products